Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure

Table 2 Immunoserological features and outcomes of enrolled patients

Case	ANA (fold)	ASMA (fold)	LKM-1 (fold)	AMA	IgG (mg/dL)	AIH score	Simplified AIH score	Corticosteroid therapy	Outcome	Weeks from onset to death
1	> 1000	-	-	-	2807	17	6	Yes	Survival	/
2	640	-	-	-	5140	16	6	No	Death	11
3	> 1000	-	UD	-	36%	15	6	No	Death	10
4	> 1000	-	UD	-	1140	13	4	No	Death	11
5	640	-	-	-	20%	13	4	No	Death	3
6	640	80	320	-	1300	11	6	No	Death	6
7	640	-	-	-	2118	15	6	Yes	Survival	/
8	> 1000	160	-	-	54%	15	6	No	Death	5
9	> 1000	-	-	-	30%	12	6	No	Death	5
10	> 1000	1000	UD	-	2026	14	6	No	Death	8
11	> 1000	-	-	-	2358	14	6	No	Death	3
12	> 1000	-	UD	-	1983	14	6	Yes	Death	22
13	> 1000	-	-	-	3014	15	6	No	Death	2
14	> 1000	320	-	-	2167	14	6	No	Death	3
15	> 1000	-	UD	-	UD	12	4	No	Death	2
16	> 1000	160	UD	-	2823	15	4	Yes	Death	19
17	> 1000	-	-	-	23%	13	5	No	Death	6
18	> 1000	-	-	-	3553	18	6	Yes	Survival	/
19	> 1000	1000	-	-	3474	19	8	Yes	Death	11
20	640	-	160	-	1456	14	6	Yes	Survival	/
21	640	-	-	-	1768	14	6	No	Death	12
22	1000	-	-	-	2776	15	6	No	Death	8

Cases 3, 5, 8, 9 and 17 presented percentage of γ-globulins. UD: Undetermined. ANA: Anti-nuclear antibody; ASMA: Anti-smooth muscle antibody; LKM: Liver kidney microsomal antibody; AMA: Antimitochondrial antibody; AIH: Autoimmune hepatitis.